Module 2: Decoding the Ames Test: From Assay Fundamentals to Regulatory Strategy
Recorded On: 03/25/2027
This presentation provides a comprehensive review of the bacterial reverse mutation (Ames) assay and emerging new approach methodologies (NAMs) for mutagenicity testing from foundational principles to regulatory strategy. Topics covered include relevant regulatory guidances, appropriate timing of Ames testing across the drug development continuum, considerations for mutagenic impurity control, assay design elements, S9 metabolic activation, and protocol modifications required for enhanced Ames assessment of nitrosamine impurities. Participants will gain a systematic framework for investigating a positive result, encompassing data review, tester strain response pattern interpretation, threshold criteria for a positive call, mechanism-of-action analysis, and selection of appropriate follow-on assays. Risk characterization strategies, including impurity classification and acceptable intake derivation, are also discussed. Case studies illustrate how positive results can be fully investigated and mitigated, and the session concludes with practical guidance on integrating genotoxicity findings into a regulatory pathway, communicating them effectively in regulatory submissions, and an overview of emerging NAMs, including error-corrected sequencing, as evolving complements to the traditional Ames battery within a broader NAM framework.
Sheroy Minocherhomji, PhD, ERT, FRSB
Senior Director of Toxicology and Pathology
Eli Lilly and Company
Dr. Sheroy Minocherhomji is a translational safety and drug development leader whose career spans the interface of drug development, investigative and regulatory toxicology, genetic toxicology, carcinogenesis and DNA repair mechanisms. As Senior Director of Toxicology and Pathology at Eli Lilly and Company, he holds a dual role, leading the Genetic Toxicology strategy for the portfolio and, as Toxicologist oversees nonclinical safety assessment across all phases of drug development for multiple therapeutic modalities.
With over a decade of industry experience, he has advanced and led the nonclinical safety of several multimodality therapeutics through clinical development, including bioconjugated oligonucleotides complex biologics and synthetics.
He is recognized for advancing the science of genotoxicity and carcinogenicity evaluation and for pioneering innovative approaches to genotoxicity risk assessment of xenobiotics. Previously, at Amgen, he established and led the Genome Instability Lab and the Genetic Toxicology Unit, where he was instrumental in the development of next-generation sequencing-based tools — including the Drug-induced Genome Instability Test (DiGIT) and Error Corrected Sequencing (ECS) — that have helped reshape testing paradigms across the genetic toxicology field.
His scientific foundations were built in academia. A Marie Curie Fellow, he earned his PhD in Health and Medical Sciences from the University of Copenhagen, focusing on epigenetic and genetic mechanisms regulating human disease-associated genes, and subsequently held appointments there as a Danish Medical Council Postdoctoral Fellow, Senior Postdoctoral Fellow, and Assistant Professor in the laboratory of Prof. Ian D. Hickson FRS, where his research focused on DNA repair mechanisms associated with replication stress. His key academic work produced seminal discoveries in synthetic lethality and genome stability, including his discovery of the novel Mitotic DNA Synthesis (MiDAS) pathway, published as first-author papers in Nature and Molecular Cell. He has over 25 peer-reviewed papers and more than 2,300 citations to date with publications in high-impact journals including Nature, Mol Cell, Nat Cell Biol, Nat Cancer, PNAS, Nature Reviews Drug Disc, EMM, RTP, ACS, and IJT.
He holds an MSc in Human Molecular Genetics from Imperial College London. He is a European Registered Toxicologist (ERT) and was elected Fellow of the Royal Society of Biology (FRSB) in 2025. He has previously been recognized with the Emerging Scientist Award from both the Genetic Toxicology Association (GTA) and the Environmental Mutagenesis and Genomics Society (EMGS). He is active within the GTA, EMGS, ACT, and SOT societies and has spoken globally at cross-industry conferences. He previously served as Chair/President of the GTA and currently serves as a HESI-GTTC Steering Committee Member and Co-Chair of several Working Groups, Co-Chair of the IQ/DruSafe TALG Metabolite Mutagenicity Discussion Group, and a member of ACT's Webinar Committee.